MapLight Therapeutics, Inc.
Last verified 2026-05-05. JSON
| Total raised | $188.2M |
|---|---|
| Latest round | Funding round, $188.2M, 2025-07-28 |
| Founded | unknown |
| Headquarters | REDWOOD CITY, CA |
| Industry | bio |
| Stage | unknown |
| Website | maplighttherapeutics.com |
MapLight Therapeutics develops small-molecule CNS drugs, led by ML-007C-MA, an M1/M4 muscarinic agonist co-formulated with a peripheral anticholinergic to limit side effects. It treats schizophrenia (Phase 2 readout 2H26) and Alzheimer's disease psychosis. MapLight synchronizes agonist and antagonist pharmacokinetics to dampen side effects.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-07-28 | Funding round | $188.2M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Funding round, $188.2M | sourced | SEC EDGAR named as publisher. Document, retrieved 2026-09-25. |
| Total raised $188.2M | sourced | SEC EDGAR named as publisher. Document, retrieved 2026-09-25. |
| Company existence | self-reported | maplighttherapeutics.com, read 2026-05-05 |
| Description | self-reported | maplighttherapeutics.com, read 2026-05-05 |
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-25Latest round: seed, $188.2M, 2025-07-28 → Funding round, $188.2M, 2025-07-28, SEC EDGAR, document, retrieved 2026-09-25 | Latest round | seed, $188.2M, 2025-07-28 → Funding round, $188.2M, 2025-07-28 | SEC EDGAR, document, retrieved 2026-09-25 |
| 2026-09-25Round: attributed → sourced, SEC EDGAR, document, retrieved 2026-09-25 | Round | attributed → sourced | SEC EDGAR, document, retrieved 2026-09-25 |
Records begin 2026-09-24. All changes